Ask Acumen

John Stuart, PhD

Manager, Quality Control

How long have you been with Acumen?

I joined Acumen in early 2022 after 30 years in commercialized small molecule and peptide pharmaceutical products.  Transitioning to monoclonal antibodies used in early phase clinical trials for Alzheimer’s required broadening my analytical expertise to not only support the clinical trial supplies, but also to support production of materials used for the analysis of clinical samples.

How does your role contribute to the overall vision of the company?

As Quality Control Manager at Acumen, I am responsible for the analytical method development, method validation, method transfer, and the analysis of products analyzed by our contract laboratories used to confirm that the clinical trial supplies meet the established quality standards to benefit patients.

Which of Acumen’s four values (People, Integrity, Innovation, and Perseverance) resonates most with your work and role?

To me Integrity is critical to ensure that the clinical trial supplies provide a safe and effective option for Alzheimer’s patients.

From your perspective, what sets our company apart in the field of Alzheimer’s research?

At Acumen our mission to bring an Alzheimer’s drug to market could be life changing for our patients.  This differs from other products that I have worked on that have improved a patient’s health but were not life altering.  The unique activity of sabirnetug sets Acumen apart from other Alzheimer’s therapies currently available.

Outside of work, what are some of your hobbies or interests that you enjoy in your free time?

I enjoy woodworking, particularly turning pens using reclaimed wood from barns and bourbon barrels.

Previous Ask Acumen Features